Mercado de terapia de reemplazo hormonal: mapeo competitivo y perspectivas estratégicas para 2031

  • Report Code : TIPRE00003836
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

La previsión del mercado de la terapia de reemplazo hormonal puede ayudar a las partes interesadas en este mercado a delinear sus estrategias de crecimiento. Se prevé que el mercado crezca de 8,46 mil millones de dólares en 2023 a 14,82 mil millones de dólares en 2031; se estima que registrará una tasa compuesta anual del 7,3 % durante 2023-2031.

La demanda mundial de terapia de reemplazo hormonal (TRH) está aumentando de manera constante debido a factores como la creciente prevalencia de trastornos hormonales, la creciente conciencia sobre las deficiencias hormonales y las mejoras en las formulaciones de TRH. Debido a sus aparentes beneficios de seguridad y eficacia, la terapia de reemplazo de hormonas bioidénticas (BHRT) se está volviendo más popular que las hormonas sintéticas. Debido a que proviene de fuentes naturales, se cree que la BHRT se parece más a las hormonas que el cuerpo produce naturalmente.

Las compañías farmacéuticas están invirtiendo en el desarrollo de nuevas formulaciones de terapia hormonal, que incluyen parches transdérmicos, geles, cremas e implantes subcutáneos para mejorar la comodidad, el cumplimiento y los perfiles de seguridad del paciente. Este factor impulsa el crecimiento del mercado de la terapia de reemplazo hormonal. En agosto de 2023, la Administración de Alimentos y Medicamentos (FDA) aprobó la solicitud abreviada de nuevo medicamento de ANI Pharmaceuticals para gel de estradiol al 0,1%. El medicamento Divigel, que figura en la lista de referencia, es una terapia hormonal con estrógenos que se utiliza para tratar los síntomas vasomotores de moderados a graves asociados con la menopausia. La forma genérica de Divigel es gel de estradiol al 0,1 %.

Impulsores de crecimiento:

La amplia gama de aplicaciones impulsa el crecimiento del mercado de la terapia de reemplazo hormonal

La terapia de reemplazo hormonal se prescribe para tratar los síntomas de la menopausia y la hormona del crecimiento. deficiencia, etc. que pueden tener un profundo impacto en la vida. Millones de mujeres utilizan la TRH, a veces durante períodos prolongados. La TRH puede prevenir la osteoporosis y mejorar la calidad de vida de varias maneras. Según Oregon Health & Science University, la deficiencia de la hormona del crecimiento (GHD) no es común y afecta aproximadamente a 50.000 adultos en los EE. UU. y aproximadamente a uno de cada 4.000 a 6.000 niños. Por lo tanto, un uso cada vez mayor de la terapia junto con la creciente prevalencia de diversos trastornos hormonales impulsa el crecimiento del mercado de tratamiento de terapia de reemplazo hormonal.

Moderación:

El alto costo de los medicamentos obstaculiza el crecimiento del mercado de terapias de reemplazo hormonal

< span>El costo de los productos HRT es relativamente alto. Por ejemplo, el precio de las recetas de terapia de reemplazo hormonal oral oscila entre 130 y 240 dólares al mes (es decir, entre 1.560 y 2.440 dólares al año), según The Menopause Center. El alto costo impide el uso regular de estos productos, lo que frena el crecimiento del mercado de la terapia de reemplazo hormonal.

Estratégico Insights

Segmentación y alcance del informe:

El análisis de mercado de la terapia de reemplazo hormonal se ha realizado considerando los siguientes segmentos: terapia, aplicación, vía de administración y usuario final.

< p>Por terapia, el mercado de la terapia de reemplazo hormonal se segmenta en reemplazo de hormonas de estrógeno, reemplazo de hormona de crecimiento, reemplazo de hormona tiroidea, reemplazo de testosterona y otros. El segmento de reemplazo de hormonas con estrógenos tuvo la mayor cuota de mercado en 2023.

El mercado de terapia de reemplazo hormonal , por aplicación, Se clasifica en menopausia, deficiencia de la hormona del crecimiento (GH), hipotiroidismo, hipogonadismo y otros. El segmento de la menopausia tuvo la mayor cuota de mercado de terapia de reemplazo hormonal en 2023 y se prevé que registre la CAGR más alta durante el período de pronóstico.

Análisis regional:

En términos de región, el alcance del informe de mercado de terapia de reemplazo hormonal incluye América del Norte, Europa, Asia Pacífico, Sur y África. Centroamérica y Medio Oriente y Asia. África. En 2023, América del Norte tenía la mayor cuota de mercado. La creciente adopción de las últimas tecnologías, la creciente prevalencia de trastornos hormonales, la adopción temprana de nuevos productos y la presencia de actores clave del mercado contribuyen al creciente tamaño del mercado de la terapia de reemplazo hormonal en América del Norte. En junio de 2023, la Administración de Alimentos y Medicamentos de EE. UU. (FDA) aprobó NGENLA (somatrogon-ghla), un análogo de la hormona del crecimiento humano que se administra una vez por semana, para su uso en el tratamiento de pacientes pediátricos de tres años o más que tienen problemas de crecimiento causados por una insuficiencia. secreción de hormona de crecimiento endógena, según un comunicado emitido por Pfizer Inc. y OPKO Health Inc.

Además, un mayor enfoque en brindar acceso a atención personalizada de calidad y fortalecer la La solución sanitaria crearía importantes oportunidades para el mercado de la terapia de reemplazo hormonal durante el período de pronóstico. En mayo de 2023, Forum Health, LLC, la primera red nacional de proveedores de medicina integral y funcional, adquirió una de las redes más grandes de clínicas de reemplazo hormonal en Texas, Hormones by Design.

Desarrollos de la industria y oportunidades futuras:

Un desarrollo estratégico por parte de los principales actores que operan en el mercado de la terapia de reemplazo hormonal , según los comunicados de prensa de la empresa, se enumeran a continuación:

    •En enero de 2024, Ascendis Pharma A/S de Dinamarca y Vector Pharma FZCO ( Vector) llegó a un acuerdo de distribución exclusiva para la comercialización de Yorvipath y Skytrofa en las naciones del Consejo de Cooperación del Golfo (CCG) de Arabia Saudita, Emiratos Árabes Unidos, Kuwait, Omán, Qatar y Bahrein. Según las condiciones de este acuerdo de distribución exclusiva, Vector utilizará su experiencia en ventas y marketing para proporcionar a los pacientes de los países del CCG Yorvipath y Skytrofa para el tratamiento del hipoparatiroidismo en adultos en el caso de Yorvipath y la deficiencia pediátrica de la hormona del crecimiento (GHD) en el caso de Yorvipath. caso de Skytrofa.

Panorama competitivo y empresas clave:< /strong>

Astrazeneca; Pfizer Inc.; Novartis AG; Abad; Tolmar Inc; Par Farmacéutica; Mayne Pharma Group Limited; Novo Nordisk A/S; Eli Lily y compañía; y Noven Pharmaceuticals, Inc. se encuentran entre las empresas destacadas descritas en el informe de mercado de terapia de reemplazo hormonal. Estas empresas se centran en desarrollar nuevas tecnologías, actualizar productos existentes y ampliar su presencia geográfica para satisfacer la creciente demanda de los consumidores en todo el mundo.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is hormone replacement therapy?

Medication that contains female hormones is known as hormone replacement treatment. When you go through menopause, your body stops producing estrogen, so you take medication to replace it. The most common menopausal symptoms that hormone therapy is used to treat are hot flashes and vaginal discomfort.

Who are the major players in the hormone replacement therapy market?

The hormone replacement therapy market majorly consists of the players, including Astrazeneca, Pfizer Inc., Novartis AG, Abbott, Tolmar Inc, Par Pharmaceutical, Mayne Pharma Group Limited, Novo Nordisk A/S, Eli Lily And Company, and Noven Pharmaceuticals, Inc.

What are the growth estimates for the hormone replacement therapy market till 2031?

The hormone replacement therapy market is expected to be valued at US$ 14.82 billion in 2031.

What was the estimated hormone replacement therapy market size in 2023?

The hormone replacement therapy market was valued at US$ 8.46 billion in 2023.

What factors drive the hormone replacement therapy market?

Increasing use of hormone replacement therapy products and increasing prevalence of hormone disorder propel the hormone replacement therapy market growth. However, high cost of medications hampers the growth of the market.

Which application segment dominates the hormone replacement therapy market?

The market, by distribution channel, is categorized into menopause, growth hormone (GH) deficiency, hypothyroidism, hypogonadism, and others. The menopause segment held the largest menopause market share in 2023, and it is anticipated to register the highest CAGR during the forecast period.

Which therapy segment dominates the hormone replacement therapy market?

By therapy, the market is segmented into estrogen hormone replacement, growth hormone replacement, thyroid hormone replacement, testosterone replacement, and others. The estrogen hormone replacement segment held a larger hormone replacement therapy market share in 2023.

The List of Companies - Hormone Replacement Therapy Market

  1. Astrazeneca
  2. Pfizer Inc.
  3. Novartis AG
  4. Abbott
  5. Tolmar Inc
  6. Par Pharmaceutical
  7. Mayne Pharma Group Limited
  8. Novo Nordisk A/S
  9. Eli Lily And Company
  10. Noven Pharmaceuticals, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports